Fulcrum Therapeutics announced it discontinued its sickle cell disease drug program due to FDA concerns about cancer risks linked to similar drugs. This led to a 51% drop in its stock price, prompting Kaplan Fox & Kilsheimer LLP to investigate potential securities violations. Investors who suffered losses are encouraged to contact the law firm. The investigation highlights regulatory challenges for treatments targeting the PRC2 complex.
Bitcoin traded near $87,200 following US officials' positive meeting with Iran, sparking a 14% weekly price gain from $75,600. CryptoQuant founder Ki Young Ju predicts a more mature bull cycle with 3-5x gains, down from previous 10x rallies, citing s...
SUI is attempting a recovery from a low range of $0.60–$0.70 after months of selling pressure. Analysts highlight the $1.00–$1.10 zone as a critical resistance level that must be reclaimed for a sustained rebound. If SUI closes weekly above $1.10 and...
Bitcoin Cash surged nearly 29% on September 22, 2026, following CME Group's announcement to list Bitcoin Cash and Uniswap futures starting October 19. This move allows professional investors to hedge positions on a regulated US exchange, driving the ...
Since 2010, bitcoin has faced 478 public declarations of its demise from figures like Peter Schiff, Warren Buffett, and institutions such as the European Central Bank. Despite these calls, $1,000 invested at each major 'bitcoin is dead' moment would ...
PEPE meme coin surged about 45% over the past week, breaking above its early-September resistance near $0.0000044 and reaching a seven-day high around $0.00000534 before pulling back slightly. Despite the retreat, PEPE remains well above its breakout...
